Patent ID: 6989139

Claim:
A radiopharmaceutical comprising a compound and a cytotoxic radioisotope; wherein said compound comprises: i) 1-10 targeting moieties; ii) a chelator, and iii) 0-1 linking groups between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor having an inhibitory constant K i of <100 nM of the formula (Ib); wherein, R 8 is independently at each occurrence OH or phenyl, optionally substituted with a bond to the linking group, provided that when R 8 is phenyl, R 10 is —C(═O)—CHR 12 —NH—(CH 3 )—COOH; R 9 and R 9′ are independently H, C 1-6 alkyl optionally substituted with a bond to the linking group, or are taken together with the carbon atom to which R 9 and R 9′ are attached to form a 5-7 atom saturated, partially unsaturated or aromatic ring system containing 0-3 heteroatoms selected from O, N, SO 2 and S, said ring system substituted with R 6 and optionally substituted with a bond to the linking group; R 10 and R 11 are independently H, or C 1-6 alkyl optionally substituted with a bond to linking group, or are taken together with the nitrogen atom to which they are attached to form a 5-7 atom saturated, partially unsaturated or aromatic ring system containing 0-2 additional heteroatoms selected from O, N, SO 2 and S, said ring system optionally substituted a bond to the linking group; or alternatively, R 9 and R 10 are taken together with the nitrogen atom and carbon atom to which they are attached to form a 5-7 atom saturated, partially unsaturated or aromatic ring system containing 0-2 additional heteroatoms selected from O, N, SO 2 and S, said ring system optionally substituted with a bond to the linking group; and R 12 is independently C 1-20 alkyl.